Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy

The main objective of this trial is to investigate the efficacy of catumaxomab by determination of the rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one cycle (four doses) of catumaxomab followed by six cycles of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy. The primary endpoint is the rate of macroscopic complete remissions of peritoneal carcinomatosis at the second diagnostic laparoscopy or laparotomy.